Chapter 4
A tissue-engineered construct is the product of several separate decisions. Someone chose a scaffold material, someone formulated a bioink, someone designed a pore network, someone sourced the cells, and someone tested the result. In most laboratories these decisions live in different notebooks, spreadsheets and instrument exports. The Phase 1 data format of WIA-BIO-006 (version 1.0.0, status Active) addresses this fragmentation. It defines five record types, called envelopes, that together describe a construct from raw material to released product: scaffold, bioink, architecture, cell source and quality test.
The standard's stated purpose is a framework covering scaffold design, biofabrication, cell culture and quality assurance for regenerative medicine. Its scope includes natural, synthetic and hybrid biomaterial scaffolds, 3D bioprinting, bioreactors, vascularization and perfusion, and quality control. Phase 1 handles the "what is it made of, and how do we know" half of that scope. Later phases handle exchange of the data.
The standard fixes a small working vocabulary, and the envelopes rely on it:
The envelopes are meant to be read together. The table below summarizes what each one answers and which link it carries to other records.
| Envelope | Question it answers | Notable cross-reference |
|---|---|---|
| Scaffold record | What is the structural material and how does it behave mechanically? | Reporting conventions of ASTM F2150 |
| Bioink formulation | What is printed, with which cells and signals? | Phase 4 §A.3 regulatory envelope for FDA-bound bioinks |
| Architecture descriptor | How is the pore network organized? | Phase 3 §A.5 target-tissue envelope |
| Cell-source descriptor | Where did the cells come from and are they fit to use? | Chain-of-custody hash tied to the contributing institution |
| Quality-test descriptor | What was measured, by whom, with what uncertainty? | Controlling ISO, ASTM or USP document |
The technical core of Phase 1 is a set of numeric descriptors chosen because they predict whether cells will attach, migrate, receive nutrients and experience a tissue-appropriate mechanical environment. Each envelope is described below in the terms of the tissue-engineering problem it addresses.
The scaffold envelope groups records by material family. The natural family includes collagen, gelatin, chitosan, alginate, fibrin, hyaluronic acid and silk fibroin. The synthetic family includes PCL, PLA, PGA, PLGA, PEG and polyurethane. The remaining families are hybrid composites and decellularized extracellular matrix. Every record carries the same canonical fields: chemical formula or polymer ratio, mean Young's modulus in Pa, ultimate strength, strain at failure, porosity in %, mean pore diameter in micrometres, interconnectivity in %, degradation half-life, and the cross-link chemistry. The listed cross-link chemistries are EDC, genipin, UV-initiated photocrosslinking, ionic and thermal.
The specification's property ranges show why a shared record matters. Materials differ by orders of magnitude, and no single material suits every tissue:
| Material | Young's modulus | Degradation | Distinguishing trait |
|---|---|---|---|
| Collagen | 1-10 MPa | 2-8 weeks | Excellent cell adhesion through RGD domains |
| Gelatin | 0.1-1 MPa | 1-4 weeks | Thermoresponsive gelation at 20-30°C |
| Chitosan | 1-2 GPa | 4-12 weeks | pH-responsive and antimicrobial |
| Alginate | 10-100 kPa | not stated | Instantaneous ionic gelation (Ca²⁺, Ba²⁺) |
| PCL | 200-400 MPa | 6-24 months | Slow degradation, easy to electrospin or print |
| PLA | 2-4 GPa | 6-12 months | Glass transition 60-65°C |
| PGA | 7 GPa | 2-4 weeks | Fast degrading, highly crystalline |
Hybrids exist to close the gaps between these rows. The specification's PCL-collagen composite (70% PCL, 30% collagen) combines PCL's mechanical strength with collagen's bioactivity, giving 50-150 MPa, 65-80% porosity and 3-6 months of degradation, with a tunable degradation rate. The gelatin-alginate blend (1:1 to 3:1 gelatin to alginate) gels by two routes, thermal and ionic, and is injectable. A record must therefore capture the polymer ratio and the cross-link route, not just a material name.
Material data follows the reporting conventions of ASTM F2150 for biomaterial scaffold characterisation. ISO 13314, a compression test for porous metals, is applied by analogy to polymeric scaffolds. The compression test reduces to three relations:
σ = F / A₀ (compressive stress, Pa)
ε = ΔL / L₀ (strain, dimensionless)
E = σ / ε (Young's modulus, Pa)The architecture descriptor is the second half of the scaffold story. It lists the pore-network topology (gyroid, Schwarz P, Schoen IWP, octet truss, stochastic foam, or hierarchical micro/macro) and the pore-size distribution as mean, standard deviation and D10/D50/D90 percentiles. It also records the surface-area-to-volume ratio, the fibre diameter for electrospun scaffolds, the fibre alignment as an anisotropy index, and the mechanical anisotropy axes. Reporting a distribution rather than a single mean matters because a scaffold with a good average pore size can still have a tail of pores too small for cells or nutrients to enter. The anisotropy fields matter for tissues whose function depends on direction.
Three derived quantities in the specification are defined by formula. Implementations should compute them identically, so the formulas are reproduced here with the variable meanings the standard gives:
P = (1 - ρ_apparent / ρ_material) × 100% (porosity)
d_pore = 6 × V_void / S_pore (average pore diameter)
I = (N_connected / N_total) × 100% (interconnectivity)
ρ_apparent : apparent density, g/cm³
ρ_material : material density, g/cm³
V_void : void volume, mm³
S_pore : pore surface area, mm²
N_connected, N_total : connected and total pore countsOne practical caution follows from the units. With V_void in mm³ and S_pore in mm², the quotient comes out in millimetres, while the specification reports pore diameter in μm. A conforming record should state its units explicitly and convert before storing. The standard sets a minimum interconnectivity of 90%, so a scaffold that falls below it fails on that descriptor even if its porosity is acceptable. Closed pores add volume but cannot carry cells or nutrients.
The bioink-formulation envelope turns a printable material into a reproducible recipe. A bioink record must list:
The rheology fields describe how the ink behaves under print conditions. A shear-thinning ink flows through the nozzle and then recovers shape on the build plate. G' and G'' show whether the deposited material behaves more like a solid or a liquid. Recording the shear rate at which viscosity was measured is essential, because a viscosity number without it cannot be compared across laboratories.
The cell-source descriptor addresses variability that is not material at all. It carries the source category (primary cells, an established cell line, or stem cells: ESC, MSC, iPSC or HSC) and donor metadata: ID, age, sex, ethnicity where consented, and lot number. It also holds the passage number, viability at thaw in %, and sterility status. Mycoplasma-free status is tied to USP <63>, and endotoxin to USP <85> at below 0.5 EU/mL. For stem cells it adds the karyotype, and the descriptor includes a differentiation marker panel. A chain-of-custody hash ties the cells to the contributing institution's signing key, so a downstream reader can see which institution supplied the cells and that the descriptor has not been altered.
Regenerative medicine is built from many small specialities: biomaterials suppliers, bioprinter makers, cell-banking organizations, contract laboratories and clinical groups. Each speciality has historically described its output in its own way. A supplier may publish a modulus as a datasheet range. A printing group may report a bioink recipe in a methods section. A clinical team may hold a donor's passage history in an internal log. A construct crossing these hand-offs loses information at each one.
The commercial pressure Phase 1 responds to is therefore comparability. A buyer of a scaffold material wants to know whether two suppliers' "collagen" scaffolds can be compared. A developer of a bioink wants the formulation to be reproducible at another site. A regulator or reviewer wants to trace a finished construct back to its cell lot and its test reports. The envelopes provide a common set of fields for each of these questions. The standard also leaves room for differentiation, since it fixes what must be reported and not which material, topology or cell type a developer should choose.
The cross-references help here. A bioink intended for FDA submission carries a pointer to the Phase 4 §A.3 regulatory envelope, so the pathway to a regulator is visible from the formulation record itself. This is a data-modelling choice. It lets a commercial party see early whether a formulation is meant for a regulated route.
The Phase 1 descriptors are meant to be matched against a target tissue. The standard gives tissue-specific figures for porosity, pore size and mechanics, and a record is only useful if it can be compared with them.
Recommended porosity ranges differ by tissue: bone 60-80%, cartilage 70-85%, skin 80-95% and liver 85-90%. Optimal pore size depends on the cell type that must colonize the scaffold:
| Cell type | Optimal pore size |
|---|---|
| Osteoblasts | 100-400 μm |
| Fibroblasts | 50-150 μm |
| Endothelial cells | 30-100 μm |
| Hepatocytes | 20-50 μm |
The mechanical requirements span an enormous range, as the specification's table shows:
| Tissue | Young's modulus | Ultimate strength | Strain at failure |
|---|---|---|---|
| Bone | 10-20 GPa | 100-200 MPa | 1-3% |
| Cartilage | 0.5-2 MPa | 5-25 MPa | 10-20% |
| Skin | 0.1-2 MPa | 1-20 MPa | 30-70% |
| Liver | 0.5-1 kPa | 1-5 kPa | 20-40% |
| Cardiac | 10-50 kPa | 10-100 kPa | 15-30% |
Reading the two tables against the material table gives practical guidance. Bone needs a stiff, slowly degrading material. PCL at 200-400 MPa and a degradation time of 6-24 months fits the healing timescale the standard cites. Pure PCL is still far below the stiffness of bone, which is why structural bone constructs rely on porosity design and mechanical testing rather than assumption. Liver and cardiac constructs sit in the kilopascal range, where alginate (10-100 kPa) and gelatin-based blends are the natural candidates. A hepatocyte scaffold that used the pore sizes appropriate for osteoblasts would be far too open, and one sized for hepatocytes would be too tight for bone ingrowth.
The architecture descriptor's cross-reference to the Phase 3 §A.5 target-tissue envelope exists to make this comparison mechanical. A consumer of the record can check whether the pore distribution, porosity and anisotropy axes match the tissue the construct is intended for, without reading the original lab report. Skin, cartilage, bone, vascular grafts and liver all appear in the specification as applications, and the same descriptors cover each.
Quality in Phase 1 means that every claim about a construct is backed by a test record citing a named method. The quality-test descriptor carries the test category, measurement method, instrument identifier, calibration record reference, the raw measurement payload (or a link to the data store), the processed result, a pass/fail flag against the standard's acceptance criteria, and the analyst signature.
| Test category | Controlling document |
|---|---|
| Sterility | USP <71> |
| Endotoxin | USP <85> |
| Cytotoxicity | ISO 10993-5 |
| Mechanical | ASTM F2150 |
| Biocompatibility (implantation) | ISO 10993-6 |
| Immunogenicity | Cited per test; no single document named |
Two rules make these descriptors auditable. A report must cite the controlling ISO, ASTM or USP document, and it must include a measurement-uncertainty budget per ISO/IEC Guide 98-3 (GUM). The second rule means a pass flag is meaningful only with its uncertainty. A modulus near an acceptance limit is a different finding when the budget is wide than when it is narrow. The calibration record reference and instrument identifier let a reviewer check that the instrument was in a known state when the measurement was taken.
Operationally, the standard wraps these records in the same companion material that accompanies every WIA standard: a glossary, a conformance test suite, a reference container with mock data, and a backwards-compatibility promise. Within the 1.x line, existing envelope shapes stay reachable, and hosts may add optional fields but not remove existing ones. This is a versioning guarantee rather than anything specific to tissue engineering, and the rest of this chapter concerns the tissue-engineering content of the records.
An implementer building Phase 1 support should start from the measurement, not the data structure. The two most common failure modes in practice are inconsistent units and missing context for a number. The standard's field list suggests a simple authoring checklist for each record, shown here as a plain worksheet rather than a wire format:
Scaffold record
material family / polymer ratio / cross-link chemistry
Young's modulus (Pa), ultimate strength, strain at failure
porosity (%), mean pore diameter (µm), interconnectivity (%)
degradation half-life
Bioink record
polymer base, concentration (% w/v), cross-linker
cell type, density (cells/mL), growth factors (ng/mL)
viscosity at print shear rate (mPa·s), G', G'' (Pa), n, yield stress
Cell-source record
source category, donor metadata, lot, passage
viability at thaw (%), mycoplasma / endotoxin status
karyotype (stem cells), marker panel, chain-of-custody hash
Quality-test record
category, method, instrument, calibration reference
raw payload, result, pass/fail, uncertainty budget, analyst signatureSeveral design points follow from the material:
jq and a POSIX shell. This lets a team test its parsers before connecting a laboratory information system.Phase 1 does not replace the laboratory protocols. Scaffold preparation steps such as extracting and purifying collagen, neutralizing to pH 7.4, and cross-linking with EDC or genipin remain the responsibility of the producing laboratory. The envelope records the outcome and the chemistry used, not the bench procedure.
Phase 1 fixes the shape of the data, and the tissue-engineering field will keep adding to what needs recording. The envelopes are built to grow. Hosts may add optional fields and new envelopes within the 1.x line, so new scaffold topologies, new cross-linking strategies or additional cell-source categories can be added without breaking existing readers. Breaking changes require a major version bump and a 12-month deprecation window.
The most likely pressure points are the places where the current descriptors are thin. Immunogenicity appears as a quality-test category without a single named controlling method. Architecture descriptors reduce a three-dimensional pore network to a topology label and a few distribution statistics. Both areas will benefit from richer data as measurement methods mature. The standard's habit of tying every result to a cited document and an uncertainty budget gives such additions a clear place to land.
Cross-standard composition is a longer-term benefit. The same identity, signing key chain and audit transport can serve other WIA family standards, so a laboratory running several of them does not need parallel infrastructure. For tissue engineering, this matters most for cell-source records, which carry personal and consent-related donor metadata and need sealed-data handling where personal data is processed.
Phase 1 turns the scattered facts about a tissue-engineered construct into five linked envelopes. The scaffold record fixes material family, mechanics, porosity, pore size and interconnectivity. The bioink record fixes the formulation, including cells, growth factors and rheology at print conditions. The architecture descriptor fixes the pore-network topology and its distribution. The cell-source descriptor fixes donor, passage, viability, sterility and custody. The quality-test descriptor ties each claim to a named ISO, ASTM or USP method and an uncertainty budget. The standard's formulas for porosity, pore diameter, interconnectivity and compressive modulus give every implementation the same arithmetic. Its tissue-specific ranges give a reader something concrete to compare each record against.
These records are still static documents. They describe a construct, but they do not yet say how a producer offers them to a consumer or how a receiving system asks for them. The next chapter moves to Phase 2, which surfaces these same envelopes through HTTPS. Because the 1.x promise keeps every Phase 1 envelope shape stable, a system built against the records described here will not need to change its data model when that interface is added.